BR112020016271A2 - Anticorpo da proteína cd38 e aplicação do mesmo - Google Patents
Anticorpo da proteína cd38 e aplicação do mesmo Download PDFInfo
- Publication number
- BR112020016271A2 BR112020016271A2 BR112020016271-0A BR112020016271A BR112020016271A2 BR 112020016271 A2 BR112020016271 A2 BR 112020016271A2 BR 112020016271 A BR112020016271 A BR 112020016271A BR 112020016271 A2 BR112020016271 A2 BR 112020016271A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- seq
- amino acid
- antigen
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810144817.4A CN110144008B (zh) | 2018-02-12 | 2018-02-12 | Cd38蛋白抗体及其应用 |
| CN201810144817.4 | 2018-02-12 | ||
| PCT/CN2019/074806 WO2019154421A1 (zh) | 2018-02-12 | 2019-02-11 | Cd38蛋白抗体及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020016271A2 true BR112020016271A2 (pt) | 2020-12-15 |
Family
ID=67547850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020016271-0A BR112020016271A2 (pt) | 2018-02-12 | 2019-02-11 | Anticorpo da proteína cd38 e aplicação do mesmo |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11713357B2 (https=) |
| EP (1) | EP3753955A4 (https=) |
| JP (1) | JP7333523B2 (https=) |
| KR (1) | KR102770962B1 (https=) |
| CN (3) | CN110144008B (https=) |
| AU (1) | AU2019218518B2 (https=) |
| BR (1) | BR112020016271A2 (https=) |
| CA (1) | CA3091492C (https=) |
| SG (1) | SG11202007443XA (https=) |
| TW (1) | TWI818952B (https=) |
| WO (1) | WO2019154421A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111303293B (zh) * | 2018-11-14 | 2022-08-30 | 杭州尚健生物技术有限公司 | 一种融合蛋白及其用途 |
| CN112876563B (zh) * | 2019-11-29 | 2022-08-16 | 康诺亚生物医药科技（成都）有限公司 | 药物组合物及其制备方法和应用 |
| CN114075283A (zh) * | 2020-08-12 | 2022-02-22 | 三生国健药业（上海）股份有限公司 | 结合人cd38的抗体、其制备方法和用途 |
| CN114075285B (zh) * | 2020-08-20 | 2023-05-30 | 瑞阳(苏州)生物科技有限公司 | 抗人cd38人源化单克隆抗体及其应用 |
| CN116547307A (zh) * | 2021-12-03 | 2023-08-04 | 南京维立志博生物科技有限公司 | 结合cd38的抗体及其用途 |
| WO2024183634A1 (en) * | 2023-03-09 | 2024-09-12 | Norroy Bioscience Co., Ltd. | Radiolabeled antibody conjugates and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| RU2402568C2 (ru) | 2004-02-06 | 2010-10-27 | МорфоСис АГ | Человеческие анти-cd38-антитела и их применение |
| KR20140066259A (ko) * | 2004-02-06 | 2014-05-30 | 모르포시스 아게 | 항-ｃｄ３８ 인간 항체 및 그의 용도 |
| JP5225069B2 (ja) * | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| CA2625681C (en) * | 2005-10-12 | 2016-08-02 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| AU2009301580B2 (en) * | 2008-10-06 | 2015-11-26 | The University Of British Columbia | Methods and systems for predicting misfolded protein epitopes |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| HUE054271T2 (hu) | 2015-05-13 | 2021-08-30 | Morphosys Ag | Mielóma Multiplex (MM) kezelése |
| EA201792546A1 (ru) * | 2015-05-20 | 2018-04-30 | Янссен Байотек, Инк. | Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей |
| CA3004152C (en) * | 2015-11-03 | 2024-04-16 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-cd38 antibodies and their uses |
| JP7679196B2 (ja) | 2017-06-08 | 2025-05-19 | ブラック ベルト セラピューティクス リミテッド | Ｃｄ３８調節抗体 |
| CN110997722B (zh) * | 2017-06-08 | 2023-09-26 | 黑带医疗有限公司 | Cd38调节抗体 |
-
2018
- 2018-02-12 CN CN201810144817.4A patent/CN110144008B/zh active Active
-
2019
- 2019-02-11 CN CN201980012880.5A patent/CN111712521B/zh active Active
- 2019-02-11 US US16/968,994 patent/US11713357B2/en active Active
- 2019-02-11 SG SG11202007443XA patent/SG11202007443XA/en unknown
- 2019-02-11 WO PCT/CN2019/074806 patent/WO2019154421A1/zh not_active Ceased
- 2019-02-11 EP EP19751277.5A patent/EP3753955A4/en active Pending
- 2019-02-11 JP JP2020565006A patent/JP7333523B2/ja active Active
- 2019-02-11 BR BR112020016271-0A patent/BR112020016271A2/pt unknown
- 2019-02-11 CA CA3091492A patent/CA3091492C/en active Active
- 2019-02-11 AU AU2019218518A patent/AU2019218518B2/en active Active
- 2019-02-11 KR KR1020207026216A patent/KR102770962B1/ko active Active
- 2019-02-11 CN CN202210259987.3A patent/CN114835809A/zh active Pending
- 2019-02-11 TW TW108104450A patent/TWI818952B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110144008B (zh) | 2021-03-19 |
| JP2021512652A (ja) | 2021-05-20 |
| CN110144008A (zh) | 2019-08-20 |
| EP3753955A4 (en) | 2021-12-08 |
| RU2020129820A3 (https=) | 2022-03-14 |
| TW201934577A (zh) | 2019-09-01 |
| JP7333523B2 (ja) | 2023-08-25 |
| EP3753955A1 (en) | 2020-12-23 |
| CN111712521A (zh) | 2020-09-25 |
| RU2020129820A (ru) | 2022-03-14 |
| CA3091492A1 (en) | 2019-08-15 |
| AU2019218518A1 (en) | 2020-10-01 |
| AU2019218518B2 (en) | 2025-07-10 |
| US11713357B2 (en) | 2023-08-01 |
| CN111712521B (zh) | 2022-03-15 |
| KR20200120937A (ko) | 2020-10-22 |
| CN114835809A (zh) | 2022-08-02 |
| WO2019154421A1 (zh) | 2019-08-15 |
| KR102770962B1 (ko) | 2025-02-24 |
| CA3091492C (en) | 2023-10-10 |
| TWI818952B (zh) | 2023-10-21 |
| US20210024645A1 (en) | 2021-01-28 |
| SG11202007443XA (en) | 2020-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3001154T3 (es) | Anticuerpo monoclonal anti-PD1, composición farmacéutica del mismo y uso del mismo | |
| CN102884085B (zh) | 抗erbb3抗体 | |
| BR112020016271A2 (pt) | Anticorpo da proteína cd38 e aplicação do mesmo | |
| BR112021003559A2 (pt) | anticorpo biespecífico, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para preparar o anticorpo biespecífico, conjugado, kit, uso do anticorpo biespecífico e composição farmacêutica | |
| BR112020024512A2 (pt) | anticorpo anti-interleucina-17a, composição farmacêutica, e, uso dos mesmos | |
| CN111018987B (zh) | 一种能与人内皮素受体特异性结合的抗体及其应用 | |
| JP2017523807A (ja) | 抗ｃｔｌａ４モノクローナル抗体またはその抗原結合断片、医薬組成物および使用 | |
| JP7533897B2 (ja) | 融合タンパク質およびその使用 | |
| JP2015525230A (ja) | デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用 | |
| ES2737649T3 (es) | Anticuerpos anti-Notch3 | |
| BR112020020637A2 (pt) | anticorpo anti-pd-l1, fragmento de ligação ao antígeno ou variante do mesmo, anticorpo biespecífico, composição farmacêutica e uso dos mesmos para aliviar ou tratar tumores | |
| WO2023241629A1 (zh) | 抗cldn18.2抗体、其药物组合物及用途 | |
| CN110615840A (zh) | 全人源的抗lag-3抗体及其应用 | |
| US20230250186A1 (en) | Cd38 protein antibody and application thereof | |
| CN114075283A (zh) | 结合人cd38的抗体、其制备方法和用途 | |
| WO2025146161A1 (en) | Antibody, antigen-binding fragment and medical use thereof | |
| HK40034156A (en) | Cd38 protein antibody and application thereof | |
| CN112867737A (zh) | 抗cd137抗体及其应用 | |
| TWI922434B (zh) | 一種融合蛋白及其用途 | |
| HK40029523B (zh) | Cd38蛋白抗体及其应用 | |
| HK40029523A (en) | Cd38 protein antibody and application thereof | |
| AU2024409193A1 (en) | Antibodies against henipaviruses | |
| CN118420764A (zh) | 抗trem2抗体及其用途 | |
| HK40057046A (en) | An anti-clta4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use | |
| HK40047979A (en) | Fusion protein and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |